2025 Q4 -tulosraportti
61 päivää sitten
‧39 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 261 | NON | DDB | ||
| 206 | NON | DDB | ||
| 184 | NON | NRD | ||
| 2 | SHB | NRD | ||
| 4 241 | SHB | DDB |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Svenska Handelsbanken AB | 10 000 | 0 | +10 000 | 0 |
| Nordnet Bank AB | 10 649 | 8 603 | +2 046 | 1 584 |
| Avanza Bank AB | 500 | 0 | +500 | 0 |
| SSW Market Making GmbH | 109 | 0 | +109 | 0 |
| DnB Bank ASA | 100 | 0 | +100 | 0 |
| Carnegie Investment Bank AB | 10 | 0 | +10 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 6 524 | 19 103 | −12 579 | 1 000 |
| Nordea Bank Abp | 0 | 186 | −186 | 0 |
| Carnegie Investment Bank AB | 10 | 0 | +10 | 0 |
| DnB Bank ASA | 100 | 0 | +100 | 0 |
| SSW Market Making GmbH | 109 | 0 | +109 | 0 |
| Avanza Bank AB | 500 | 0 | +500 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 t sittenHere are the most likely reasons for the maneuver: 1. Signaling effect: "Unity & Commitment" By pooling their shares in a company where all significant decisions must be taken unanimously, Andreas Kjær (CSO) and Ulrich Krasilnikoff (CEO) send a strong signal to the market. They commit to each other and to Curasight's future. For an investor, it means that the two most important people in the company are "locked" together and cannot suddenly act against each other's interests. 2. Simplification of the ownership structure (Cap Table) When large funds or potential Big Pharma partners look at Curasight, it looks more professional and stable that the controlling founder power (approx. 28.33 %) is consolidated in one place. This makes it easier to administer everything from general meetings to potential future share sales or partnership agreements. 3. Tax and wealth optimization In Denmark, there are significant tax advantages to owning shares through a holding company (if one owns over 10 %). Tax-free reinvestment: Dividends or proceeds from a potential partial sale can often be received tax-free in the holding company, so the money can be reinvested in Curasight or other projects without first being taxed as personal income. 4. Preparation for M&A (Mergers or acquisitions) One often sees this type of consolidation if a company is preparing for something bigger. If a buyer (e.g., a large pharmaceutical company) wants to acquire a controlling stake, it is much easier to negotiate with one entity (Curacap II) than with several individual owners and their respective smaller holding companies. 5. Voting block effect Even though they each had many shares before, they now stand as a united block. This gives them a stronger voice towards new large investors (such as Fenja Capital or others who have recently joined). This ensures that the founders retain strategic control over the company's direction. In short: It doesn't change who decides "tomorrow", but it makes Curasight a more streamlined and "mature" investment case for the really big players. It removes noise in the ownership structure and cements the partnership between the CEO and CSO.
·1 päivä sittenIt's probably also positive, even though the ownership structure doesn't mean that much....😁
·1 päivä sitten · MuokattuThe changes in the ownership structure mostly resemble an internal restructuring and should not be interpreted negatively, rather the opposite. Such movements are often seen leading up to important data points, where ownership is "prepared" for possible strategic processes. In the Curasight case, close to Phase I-readout, it's probably about positioning, and not about a lack of confidence in the data. This and the other restructurings in the ownership fit well into a process of dialogue with Big Pharma (partner agreement/acquisition). A partner agreement for financing the Basket trial is probably the most likely... but if Phase I data is very convincing, we can naturally be surprised!
3 päivää sitten3 päivää sittenTämä julkaisu on poistettu.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
61 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenHere are the most likely reasons for the maneuver: 1. Signaling effect: "Unity & Commitment" By pooling their shares in a company where all significant decisions must be taken unanimously, Andreas Kjær (CSO) and Ulrich Krasilnikoff (CEO) send a strong signal to the market. They commit to each other and to Curasight's future. For an investor, it means that the two most important people in the company are "locked" together and cannot suddenly act against each other's interests. 2. Simplification of the ownership structure (Cap Table) When large funds or potential Big Pharma partners look at Curasight, it looks more professional and stable that the controlling founder power (approx. 28.33 %) is consolidated in one place. This makes it easier to administer everything from general meetings to potential future share sales or partnership agreements. 3. Tax and wealth optimization In Denmark, there are significant tax advantages to owning shares through a holding company (if one owns over 10 %). Tax-free reinvestment: Dividends or proceeds from a potential partial sale can often be received tax-free in the holding company, so the money can be reinvested in Curasight or other projects without first being taxed as personal income. 4. Preparation for M&A (Mergers or acquisitions) One often sees this type of consolidation if a company is preparing for something bigger. If a buyer (e.g., a large pharmaceutical company) wants to acquire a controlling stake, it is much easier to negotiate with one entity (Curacap II) than with several individual owners and their respective smaller holding companies. 5. Voting block effect Even though they each had many shares before, they now stand as a united block. This gives them a stronger voice towards new large investors (such as Fenja Capital or others who have recently joined). This ensures that the founders retain strategic control over the company's direction. In short: It doesn't change who decides "tomorrow", but it makes Curasight a more streamlined and "mature" investment case for the really big players. It removes noise in the ownership structure and cements the partnership between the CEO and CSO.
- ·1 päivä sittenIt's probably also positive, even though the ownership structure doesn't mean that much....😁·1 päivä sitten · MuokattuThe changes in the ownership structure mostly resemble an internal restructuring and should not be interpreted negatively, rather the opposite. Such movements are often seen leading up to important data points, where ownership is "prepared" for possible strategic processes. In the Curasight case, close to Phase I-readout, it's probably about positioning, and not about a lack of confidence in the data. This and the other restructurings in the ownership fit well into a process of dialogue with Big Pharma (partner agreement/acquisition). A partner agreement for financing the Basket trial is probably the most likely... but if Phase I data is very convincing, we can naturally be surprised!
- 3 päivää sitten3 päivää sittenTämä julkaisu on poistettu.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 261 | NON | DDB | ||
| 206 | NON | DDB | ||
| 184 | NON | NRD | ||
| 2 | SHB | NRD | ||
| 4 241 | SHB | DDB |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Svenska Handelsbanken AB | 10 000 | 0 | +10 000 | 0 |
| Nordnet Bank AB | 10 649 | 8 603 | +2 046 | 1 584 |
| Avanza Bank AB | 500 | 0 | +500 | 0 |
| SSW Market Making GmbH | 109 | 0 | +109 | 0 |
| DnB Bank ASA | 100 | 0 | +100 | 0 |
| Carnegie Investment Bank AB | 10 | 0 | +10 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 6 524 | 19 103 | −12 579 | 1 000 |
| Nordea Bank Abp | 0 | 186 | −186 | 0 |
| Carnegie Investment Bank AB | 10 | 0 | +10 | 0 |
| DnB Bank ASA | 100 | 0 | +100 | 0 |
| SSW Market Making GmbH | 109 | 0 | +109 | 0 |
| Avanza Bank AB | 500 | 0 | +500 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
61 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenHere are the most likely reasons for the maneuver: 1. Signaling effect: "Unity & Commitment" By pooling their shares in a company where all significant decisions must be taken unanimously, Andreas Kjær (CSO) and Ulrich Krasilnikoff (CEO) send a strong signal to the market. They commit to each other and to Curasight's future. For an investor, it means that the two most important people in the company are "locked" together and cannot suddenly act against each other's interests. 2. Simplification of the ownership structure (Cap Table) When large funds or potential Big Pharma partners look at Curasight, it looks more professional and stable that the controlling founder power (approx. 28.33 %) is consolidated in one place. This makes it easier to administer everything from general meetings to potential future share sales or partnership agreements. 3. Tax and wealth optimization In Denmark, there are significant tax advantages to owning shares through a holding company (if one owns over 10 %). Tax-free reinvestment: Dividends or proceeds from a potential partial sale can often be received tax-free in the holding company, so the money can be reinvested in Curasight or other projects without first being taxed as personal income. 4. Preparation for M&A (Mergers or acquisitions) One often sees this type of consolidation if a company is preparing for something bigger. If a buyer (e.g., a large pharmaceutical company) wants to acquire a controlling stake, it is much easier to negotiate with one entity (Curacap II) than with several individual owners and their respective smaller holding companies. 5. Voting block effect Even though they each had many shares before, they now stand as a united block. This gives them a stronger voice towards new large investors (such as Fenja Capital or others who have recently joined). This ensures that the founders retain strategic control over the company's direction. In short: It doesn't change who decides "tomorrow", but it makes Curasight a more streamlined and "mature" investment case for the really big players. It removes noise in the ownership structure and cements the partnership between the CEO and CSO.
- ·1 päivä sittenIt's probably also positive, even though the ownership structure doesn't mean that much....😁·1 päivä sitten · MuokattuThe changes in the ownership structure mostly resemble an internal restructuring and should not be interpreted negatively, rather the opposite. Such movements are often seen leading up to important data points, where ownership is "prepared" for possible strategic processes. In the Curasight case, close to Phase I-readout, it's probably about positioning, and not about a lack of confidence in the data. This and the other restructurings in the ownership fit well into a process of dialogue with Big Pharma (partner agreement/acquisition). A partner agreement for financing the Basket trial is probably the most likely... but if Phase I data is very convincing, we can naturally be surprised!
- 3 päivää sitten3 päivää sittenTämä julkaisu on poistettu.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 261 | NON | DDB | ||
| 206 | NON | DDB | ||
| 184 | NON | NRD | ||
| 2 | SHB | NRD | ||
| 4 241 | SHB | DDB |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Svenska Handelsbanken AB | 10 000 | 0 | +10 000 | 0 |
| Nordnet Bank AB | 10 649 | 8 603 | +2 046 | 1 584 |
| Avanza Bank AB | 500 | 0 | +500 | 0 |
| SSW Market Making GmbH | 109 | 0 | +109 | 0 |
| DnB Bank ASA | 100 | 0 | +100 | 0 |
| Carnegie Investment Bank AB | 10 | 0 | +10 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 6 524 | 19 103 | −12 579 | 1 000 |
| Nordea Bank Abp | 0 | 186 | −186 | 0 |
| Carnegie Investment Bank AB | 10 | 0 | +10 | 0 |
| DnB Bank ASA | 100 | 0 | +100 | 0 |
| SSW Market Making GmbH | 109 | 0 | +109 | 0 |
| Avanza Bank AB | 500 | 0 | +500 | 0 |